Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

5-year follow-up checks if imlifidase helps kidney transplants last longer

NCT ID NCT05937750

Disease control Sponsor: Hansa Biopharma AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 150 people who received imlifidase before a kidney transplant to see how long their new kidney works. Researchers will check for graft failure (return to dialysis, re-transplant, or kidney removal) over 5 years. A separate group of similar patients not receiving imlifidase is also included for comparison.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 76 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed Informed Consent obtained before any trial-related procedures * Willingness and ability to comply with the protocol * Previously transplanted in the clinical trial 20-HmedIdeS-19 (PAES) Exclusion Criteria: * Inability by the judgment of the investigator to participate in the trial for other reasons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long term efficacy and safety

Contacts and locations

Locations

  • Azienda Ospedaliera di Padova

    Padova, 35128, Italy

  • Azienda Ospedaliero - Universitaria di Parma

    Parma, 43100, Italy

  • Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume

    Bois-Guillaume, Normandy, 76230, France

  • Erasmus University Medical Center

    Rotterdam, 3015 GD, Netherlands

  • Hospital Del Mar, Servicio de Nefrología

    Barcelona, 08003, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, 28041, Spain

  • Hospital Universitario del Vall d´Hebron

    Barcelona, 08035, Spain

  • Hôpital Necker - Enfants Malades

    Paris, 75015, France

  • Karolinska University Hospital,

    Huddinge, Stockholm County, 14157, Sweden

  • Leiden University Medical Center

    Leiden, 2333 ZA, Netherlands

  • Medizinische Universitaet Wien

    Vienna, 1090, Austria

  • Nephrology Clinic Vídeňská 1958/9

    Prague, 140-21, Czechia

  • Unidad de Trasplante Renal

    Barcelona, 08036, Spain

  • Uppsala University Hospital

    Uppsala, 751 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.